Published in Front Aging Neurosci on June 08, 2017
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science (2005) 14.43
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci (2005) 11.55
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci (2007) 11.24
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol (2004) 9.62
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41
TLR signaling pathways. Semin Immunol (2004) 9.08
The classical complement cascade mediates CNS synapse elimination. Cell (2007) 9.06
Synaptic pruning by microglia is necessary for normal brain development. Science (2011) 7.35
Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology (1988) 6.79
Nomenclature of monocytes and dendritic cells in blood. Blood (2010) 6.63
Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol (2015) 4.94
Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol (2009) 4.88
Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience (1990) 4.52
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 4.38
The myeloid cells of the central nervous system parenchyma. Nature (2010) 3.80
Microglial interactions with synapses are modulated by visual experience. PLoS Biol (2010) 3.59
Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity (2009) 3.51
Debris clearance by microglia: an essential link between degeneration and regeneration. Brain (2008) 3.36
Monocytes and macrophages: developmental pathways and tissue homeostasis. Nat Rev Immunol (2014) 3.27
Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J Neurochem (2002) 3.14
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 2.95
Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev (1995) 2.92
Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2008) 2.91
Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol (2003) 2.90
Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res (1999) 2.80
Changing face of microglia. Science (2010) 2.79
Innate immunity in the central nervous system. J Clin Invest (2012) 2.77
Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna) (2003) 2.75
Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci (2000) 2.75
Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci (1985) 2.70
Use of ibuprofen and risk of Parkinson disease. Neurology (2011) 2.70
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res (1979) 2.61
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis (2005) 2.59
The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol (2003) 2.58
Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol (2005) 2.54
Role of microglia in neurotrauma. Neurotherapeutics (2010) 2.53
Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord (2004) 2.41
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol (2015) 2.18
Microglial phenotype: is the commitment reversible? Trends Neurosci (2006) 2.18
Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One (2010) 2.15
Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nat Med (1996) 2.14
Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A (1996) 2.10
Neuroinflammatory processes in Parkinson's disease. Ann Neurol (2003) 2.10
mRNA up-regulation of MHC II and pivotal pro-inflammatory genes in normal brain aging. Neurobiol Aging (2006) 2.06
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.01
Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy. J Neurosci (2009) 2.00
Defining GM-CSF- and macrophage-CSF-dependent macrophage responses by in vitro models. J Immunol (2012) 1.93
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A (2006) 1.92
Dynamic complexity of the microglial activation response in transgenic models of amyloid deposition: implications for Alzheimer therapeutics. J Neuropathol Exp Neurol (2005) 1.90
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol (2006) 1.87
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
Neurotransmitter receptors on microglia. Trends Neurosci (2007) 1.84
Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm Suppl (2000) 1.83
Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J (2002) 1.79
CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol (2012) 1.78
Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem (2005) 1.78
Microglia: Multiple roles in surveillance, circuit shaping, and response to injury. Neurology (2013) 1.77
Review: activation patterns of microglia and their identification in the human brain. Neuropathol Appl Neurobiol (2013) 1.77
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett (1994) 1.73
Characterization of the microglial phenotype under specific pro-inflammatory and anti-inflammatory conditions: Effects of oligomeric and fibrillar amyloid-beta. J Neuroimmunol (2009) 1.71
Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci (2012) 1.71
Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun (2013) 1.66
Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging (2007) 1.63
LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci (2012) 1.61
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem (2004) 1.61
The MPTP model of Parkinson's disease. Brain Res Mol Brain Res (2005) 1.60
Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation (2013) 1.59
Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol (2003) 1.57
Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J Neurosci (2007) 1.55
Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem (1998) 1.52
Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology (2007) 1.52
CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J Neurosci (2007) 1.51
Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature (1984) 1.50
Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells. J Neuroinflammation (2015) 1.50
Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol (2001) 1.47
Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol (2008) 1.45
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci (2009) 1.42
Inflammation in Parkinson's diseases and other neurodegenerative diseases: cause and therapeutic implications. Curr Pharm Des (2007) 1.41
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation (2005) 1.41
Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J Neuroinflammation (2010) 1.41
The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet (2005) 1.40
The influence of microglia on the pathogenesis of Parkinson's disease. Prog Neurobiol (2009) 1.39
Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology (2010) 1.38
Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann Neurol (2011) 1.38
Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep (2012) 1.36
1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun (1990) 1.36
TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis (2007) 1.35
Production and functions of IL-17 in microglia. J Neuroimmunol (2007) 1.34
Differential gene expression in LPS/IFNgamma activated microglia and macrophages: in vitro versus in vivo. J Neurochem (2009) 1.34
Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia. Glia (2012) 1.32
In vivo microglia activation in very early dementia with Lewy bodies, comparison with Parkinson's disease. Parkinsonism Relat Disord (2012) 1.32
Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse (2001) 1.31
Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A (2009) 1.31